---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-050987"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:15:38.268509+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics completes stock option exchange; 93% of eligible underwater options surrendered.

## Summary
- Option exchange program closed; 3,880,332 shares surrendered (~93% of eligible) for 1,906,153 replacement options.
- CEO Lawrence M. Blatt surrendered 854,250 options, received 421,100 replacement options; other NEOs and directors also participated.
- Exchange ratios were 1.4-for-1 or 3.4-for-1 based on exercise price; all surrendered options were underwater.
- Replacement options have a new one-year cliff vest from grant date (Feb 28, 2024), then follow original schedule.

## SEC filing metadata
- accession: 0001193125-24-050987
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312524050987/0001193125-24-050987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312524050987/d766112d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-050987
- JSON: https://secwatch.observer/filing/0001193125-24-050987.json
- Plain text: https://secwatch.observer/filing/0001193125-24-050987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.